If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
== Mechanism of plasminogen activation == Full length plasminogen comprises seven domains. In addition to a C-terminal chymotrypsin-like serine protease domain, plasminogen contains an N-terminal Pan Apple domain (PAp) together with five Kringle domains (KR1-5). The Pan-Apple domain contains important determinants for maintaining plasminogen in the closed form, and the kringle domains are responsible for binding to lysine residues present in receptors and substrates. The X-ray crystal structure of closed plasminogen reveals that the PAp and SP domains maintain the closed conformation through interactions made throughout the kringle array . Chloride ions further bridge the PAp / KR4 and SP / KR2 interfaces, explaining the physiological role of serum chloride in stabilizing the closed conformer. The structural studies also reveal that differences in glycosylation alter the position of KR3. These data help explain the functional differences between the type I and type II plasminogen glycoforms. In closed plasminogen, access to the activation bond (R561/V562) targeted for cleavage by tPA and uPA is blocked through the position of the KR3/KR4 linker sequence and the O-linked sugar on T346. The position of KR3 may also hinder access to the activation loop. The Inter-domain interactions also block all kringle ligand-binding sites apart from that of KR-1, suggesting that the latter domain governs pro-enzyme recruitment to targets.
==== United States ==== 3,4-DMA is not an explicitly controlled substance in the United States, but can be considered a Schedule I controlled substance as a positional isomer of 2,5-dimethoxyamphetamine (2,5-DMA) in this country.
== Protein structure databases == A protein structure database is a database that is modeled around the various experimentally determined protein structures. The aim of most protein structure databases is to organize and annotate the protein structures, providing the biological community access to the experimental data in a useful way. Data included in protein structure databases often includes 3D coordinates as well as experimental information, such as unit cell dimensions and angles for x-ray crystallography determined structures. Though most instances, in this case either proteins or a specific structure determinations of a protein, also contain sequence information and some databases even provide means for performing sequence based queries, the primary attribute of a structure database is structural information, whereas sequence databases focus on sequence information, and contain no structural information for the majority of entries. Protein structure databases are critical for many efforts in computational biology such as structure based drug design, both in developing the computational methods used and in providing a large experimental dataset used by some methods to provide insights about the function of a protein.
SELDI can be seen as a combination of solid-phase chromatography and TOF-MS. The sample is applied to a modified chip surface, which allows for the specific binding of proteins from the sample to the surface. Contaminants and unbound proteins are then washed away. After washing the sample, an energy absorbing matrix, such as sinapinic acid (SPA) or α-Cyano-4-hydroxycinnamic acid (CHCA), is applied to the surface and allowed to crystallize with the sample. Alternatively, the matrix can be attached to the sample surface by covalent modification or adsorption before the sample is applied. The sample is then irradiated by a pulsed laser, causing ablation and desorption of the sample and matrix.
Sources: en.wikipedia.org
=== Catalysis === Organic cages act as nano reactors for catalytic transformations. The confined environment enhances reaction rates and selectivity through concentration effects in the cavity, specific orientation of reactants, stabilization of transition states, and control over product distribution. The well-defined cavity creates a unique microenvironment that can accelerate reactions and influence product selectivity. Asymmetric catalysis benefits from chiral cage environments, enabling stereoselective transformations. The catalytic activity can be tuned through modification of cage structure and functionalization of the cavity interior. Integration of catalytic sites within the cage framework allows for size-selective catalysis, where only appropriately sized substrates can access the active sites.
Ishibashi T, Yokoi N, Kinoshita S (2003). "Comparison of the effects of topical levobunolol and timolol solution on the human ocular surface". Cornea. 22 (8): 709–15. doi:10.1097/00003226-200311000-00001. PMID 14576520. S2CID 25444383. Ogasawara H, Yoshida A, Fujio N, Konno S, Ishiko S (1999). "[Effect of topical levobunolol on retinal, optic nerve head, and choroidal circulation in normal volunteers]". Nippon Ganka Gakkai Zasshi. 103 (7): 544–50. PMID 10443129. Leung M, Grunwald J (1997). "Short-term effects of topical levobunolol on the human retinal circulation". Eye. 11 (3): 371–6. doi:10.1038/eye.1997.78. PMID 9373479.
The goal of cheese making is to control the spoiling of milk into cheese. The milk is traditionally from a cow, goat, sheep, or buffalo, although, in theory, cheese could be made from the milk of any mammal. Cow's milk is most commonly used worldwide. The cheesemaker's goal is a consistent product with specific characteristics (appearance, aroma, taste, texture). The process used to make a Camembert will be similar to, but not quite the same as, that used to make Cheddar. Some cheeses may be deliberately left to ferment from naturally airborne spores and bacteria; this approach generally leads to a less consistent product but one that is valuable in a niche market.
=== Supercritical desalination === The solubility of dissolved ions drops precipitously once a fluid becomes supercritical. This effect can be used to precipitate salts from high salinity desalination streams, with solubility of different salts decreasing rapidly as water approaches supercritical temperatures. Complex cycle design can enable selective precipitation and improved heat recovery. Some very saline water sources like produced water also have high hydrocarbon content, which can be oxidized by supercritical desalination.
=== Filming === Filming began with the first round, which was shot through July 18–22, 2024, inside of Allegiant Stadium in Las Vegas, with a total of 2,000 contestants attending. This round is released on YouTube. The Beast City part of the competition that was featured in the first four, sixth, eighth and ninth episode of the TV series as well as a second YouTube video promoting the series featuring 20 eliminated contestants competing for $500,000, was filmed with the remaining 1,000 contestants at Downsview Park Studios in Toronto, Ontario, Canada, in August of that year. The "Beast Island" part of the competition featured in the fourth to sixth episodes, along with the tenth episode of the show was filmed at the uninhabited La Vivienda Island, which is located in the Pearl Islands, Panama. The filming broke 44 Guinness World Records, including the largest physical cash prize on set ($5,000,000), the most prize money turned down on a competitive reality TV show ($1,000,000), the largest prize fund awarded for a competitive reality TV show ($10,000,000), and the most money won in a single episode of a competitive reality TV show ($2,020,000), and a page in the 2026 Guinness Book of World Records was focused on the show.
Sources: en.wikipedia.org
=== 4th Congress (1986) === The Political Report to the Fourth Congress (Nov. 1986) stated "For the first time there is a possibility of building a truly revolutionary party on the basis of the objective communist movement. That movement is nothing less than the galvanizing struggles of 50 million dispossessed, hungry, homeless and unemployed—the most oppressed and exploited workers. This must be the firm foundation of our Party.” Here the CLP begins to clearly move away from the 3rd International conception of the industrial workers as the foundation of the communist party. With the application of electronics to the productive process, which accelerated in the 1970s and 80s, the industrial workers began to disappear from the workforce. Many left groups moved to base themselves in whatever unions remained, in spite of the fact that both public and private sector unions were radically declining in membership. The CLP began to seriously grapple with the transformation that was occurring within the working class. In the pamphlet, "Documents of the Fourth Congress,” the article "Explanation of the Party Program” quotes an 1890 letter written by Engels: "It is far more important that the movement should spread, proceed harmoniously, take root and embrace as much as possible the whole American proletariat than that it should start and proceed, from the beginning, on theoretically perfectly correct lines. There is no better road to theoretical clearness of comprehension than to learn by one’s own mistakes.
The Recommended Daily Intake (RDA) for preformed supplemental vitamin A for adult men and women is 900 and 700 Retinol Activity Units(RAE)/day, respectively, or about 3,000 IU and 2,300 IU. In pregnancy, the vitamin A RDA is 750–770 RAE/day (about 2,500–2,550 IU). During lactation, the RDA increases to 1,200–1,300 RAE/day (about 4,000–4,300 IU, with differences depending on age). Retinol Activity Units can only be converted to IU (International Units) when the source of the vitamin A is known. The IU values listed above do not apply to food sources of vitamin A. Too much vitamin A in retinoid form can be harmful. The body converts the dimerized form, carotene, into vitamin A as it is needed, so high levels of carotene are not toxic, whereas the ester (animal) forms are. The livers of certain animals, especially those adapted to polar environments, such as polar bears and seals, often contain amounts of vitamin A that would be toxic to humans. Thus, vitamin A toxicity is typically reported in Arctic explorers and people taking large doses of synthetic vitamin A. The first documented death possibly caused by vitamin A poisoning was that of Xavier Mertz, a Swiss scientist, who died in January 1913 on an Antarctic expedition that had lost its food supplies and fell to eating its sled dogs. Mertz may have consumed lethal amounts of vitamin A by eating the dogs' livers. Vitamin A acute toxicity occurs when a person ingests vitamin A in large amounts more than the daily recommended value in the threshold of 25,000 IU/kg or more.
Even the territorial integrity of the country was in danger: On 7 March 1849, an imperial proclamation was issued in the name of the Emperor Francis Joseph, according to the new proclamation, the territory of Kingdom of Hungary would be carved up and administered by five military districts, while the Principality of Transylvania would be reestablished. These events represented a clear and obvious existential threat for the Hungarian state. The stadion constitution abolished Hungary’s separate constitutional statehood and reduced the Hungarian state to the status of a typical Habsburg province/crownland within a centralized Austrian Empire. The new constrained Stadion Constitution of Austria, the revocation of the April laws and the Austrian military campaign against the Kingdom of Hungary resulted in the fall of the pacifist Batthyány government (which sought agreement with the court) and led to the sudden emergence of Lajos Kossuth's followers in the Hungarian parliament, who demanded the full independence of Hungary. The Austrian military intervention in the Kingdom of Hungary resulted in strong anti-Habsburg sentiment among Hungarians, thus the events in Hungary grew into a war for total independence from the Habsburg dynasty.
=== Orthologs === There are currently 193 organisms that are known to be orthologs of EPCIP. The orthologs of EPCIP are deuterostome animals in the clade Chordata. Table 3 shows a range of EPCIP orthologs, their NCBI accession numbers, sequence lengths, and sequence identity to the EPCIP human protein. At this time, EPCIP is not known to have any protostome or invertebrate orthologs.
=== Numbers of new drugs === Under the ODA and EU legislation, many orphan drugs have been developed, including drugs to treat glioma, multiple myeloma, cystic fibrosis, phenylketonuria, snake venom poisoning, and idiopathic thrombocytopenic purpura. The Pharmaceutical Executive opines that the "ODA is nearly universally acknowledged to be a success". Before the US Congress enacted the ODA in 1983, only 38 drugs were approved in the US specifically to treat orphan diseases. In the US, from January 1983 to June 2004, 249 orphan drugs received marketing authorization and 1,129 received different orphan drug designations, compared to fewer than ten such products in the decade prior to 1983. From 1983 until May 2010, the FDA approved 353 orphan drugs and granted orphan designations to 2,116 compounds. As of 2010, 200 of the roughly 7,000 officially designated orphan diseases have become treatable. Critics have questioned whether orphan drug legislation was the real cause of this increase, claiming that many of the new drugs were for disorders which were already being researched anyway, and would have had drugs developed regardless of the legislation, and whether the ODA has truly stimulated the production of non-profitable drugs; the act also has been criticised for allowing some pharmaceutical companies to make a large profit off drugs which have a small market but sell for a high price.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.